The study included 76 patients with lymphoma and 30 with multiple myeloma who underwent transplantation at Shanxi Province Cancer Hospital between January 2015 and December 2023. Following propensity score matching, 53 patients received intravenous melphalan and 53 received oral melphalan. The primary endpoint was 3-year progression-free survival, and follow-up continued through September 2024.

Lymphoma patients received BEAM conditioning containing carmustine, etoposide, cytarabine and a total of 140 mg/m² melphalan on day −1. The dose was delivered as one intravenous infusion or two equal oral doses approximately 12 hours apart under fasting conditions. Multiple myeloma patients received 200 mg/m² over two days, either as two daily intravenous infusions or four divided oral doses.

Route assignment was not randomized. It reflected patient preference, financial considerations, discussion of off-label oral use and intermittent shortages of intravenous melphalan. Propensity matching addressed measured baseline factors but did not remove all imbalances, including sex distribution in non-Hodgkin lymphoma, time to transplantation in Hodgkin lymphoma and M-component type in multiple myeloma.

All matched patients achieved hematopoietic reconstitution. Among patients with lymphoma, median neutrophil engraftment took 10 days with intravenous melphalan and 12 days with oral melphalan (p = 0.025). In multiple myeloma, median platelet engraftment took 11 and 14 days, respectively (p = 0.021), while neutrophil engraftment was 11 days in both groups. Red blood cell and platelet transfusion requirements did not differ significantly.

Grade 3–4 anemia was more frequent with oral melphalan, affecting 37.74% of patients versus 18.87% with intravenous treatment (p = 0.031). Febrile neutropenia was less frequent with oral melphalan, occurring in 35.85% versus 56.60% (p = 0.032). Within the oral group, grade 3–4 anemia was associated with delayed platelet engraftment, appearing in 62.5% of patients with delayed engraftment and 21.4% of those without it (p = 0.008).

Gastrointestinal toxicity followed the opposite pattern. Diarrhea occurred in 18.87% of oral recipients and 37.74% of intravenous recipients (p = 0.031), while oral mucositis occurred in 7.55% and 33.96%, respectively (p = 0.001). Nausea or vomiting, elevated transaminases and electrolyte disorders did not differ significantly. No deaths occurred before day 100.

At day 100, complete response rates were 92.11% with intravenous melphalan and 81.58% with oral treatment in lymphoma (p = 0.123). In multiple myeloma, both groups had complete response rates of 40.00% (p = 1.000). Estimated 3-year progression-free survival was 78.9% versus 81.6% in lymphoma and 66.7% versus 73.3% in multiple myeloma; corresponding overall survival estimates were 89.5% versus 86.8% and 86.7% versus 80.0%. None of these comparisons was statistically significant.

Multivariable analyses did not identify melphalan route as an independent predictor of progression-free or overall survival. However, the retrospective single-center design, residual confounding, small subgroups, unequal follow-up in lymphoma and absence of pharmacokinetic measurements limit interpretation. Oral melphalan has reported bioavailability of 20–60%, so the observed clinical similarity does not demonstrate bioequivalence. The authors called for prospective multicenter studies with pharmacokinetic assessment.

Subject of Research: Comparative outcomes and toxicity of oral versus intravenous melphalan conditioning for autologous stem cell transplantation in lymphoma and multiple myeloma

Article Title: Oral versus intravenous melphalan for autologous stem cell transplantation conditioning in lymphoma and multiple myeloma: a retrospective cohort study

Article References: Wang, J., Guo, Y., Zhao, J., Wen, X., Su, L., Hao, Z., & Yang, J. (2026). Oral versus intravenous melphalan for autologous stem cell transplantation conditioning in lymphoma and multiple myeloma: a retrospective cohort study. Frontiers in Oncology, 16, Article 1923679. https://doi.org/10.3389/fonc.2026.1923679

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1923679

Keywords: melphalan, autologous stem cell transplantation, lymphoma, multiple myeloma, oral administration, intravenous administration, engraftment, treatment toxicity, propensity score matching, survival outcomes, Oral, versus

Researchers used recursive partitioning analysis to divide the cohort into three groups using preselected clinicopathological variables: age, FIGO stage, tumor size, lympho-vascular invasion, deep stromal invasion and perineural invasion. The low-risk group comprised 96 patients without lympho-vascular invasion or deep stromal invasion. The intermediate-risk group included 70 patients with lympho-vascular invasion and deep stromal invasion but without perineural invasion. The high-risk group consisted of 33 patients with all three pathological features. Relative to the low-risk group, the reported hazard ratios were 3.60 for the intermediate-risk group (95% CI 1.95–6.67; p<0.001) and 6.22 for the high-risk group (95% CI 3.23–11.95; p<0.001).

Postoperative radiotherapy did not significantly improve survival in the overall cohort, with all reported p-values greater than 0.05. The association differed by risk group: among the 33 high-risk patients, radiotherapy was associated with a five-year overall survival of 41.9%, compared with 0% among those who did not receive radiotherapy. The reported hazard ratio for postoperative radiotherapy in this subgroup was 0.22 (95% CI 0.08–0.58; p<0.001). No mortality reduction was observed in the intermediate-risk group (p=0.890) or the low-risk group (p=0.980).

The abstract describes a two-institution retrospective design rather than a randomized trial. Evaluations of radiotherapy used stratified Kaplan–Meier analysis and Cox proportional hazards models, while variables in the risk model were weighted according to hazard ratios from univariate and multivariable Cox regression. The findings therefore identify patient subgroups in which postoperative radiotherapy was associated with survival differences, but they do not establish that radiotherapy caused the observed outcomes. The abstract itself calls for prospective validation before the risk-stratified approach can be considered established, and it does not provide information about treatment allocation, confounding, toxicity or the reasons for withholding radiotherapy.

Subject of Research: Risk-stratified postoperative radiotherapy associations in limited-stage high-grade neuroendocrine cervical carcinoma

Article Title: Postoperative radiotherapy for limited-stage high-grade neuroendocrine cervical carcinoma: a retrospective multi-center study from two Chinese institutions

Article References: Yang, X., Wen, J., Tang, Q., Aili, Y., Chen, M., Cao, X., Chen, Y., Li, Y., Ren, Y., & He, S. (2026). Postoperative radiotherapy for limited-stage high-grade neuroendocrine cervical carcinoma: a retrospective multi-center study from two Chinese institutions. BMC Cancer. https://doi.org/10.1186/s12885-026-16959-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16959-3

Keywords: neuroendocrine cervical carcinoma, postoperative radiotherapy, high-grade cervical cancer, recursive partitioning analysis, lympho-vascular invasion, deep stromal invasion, perineural invasion, survival, retrospective cohort, risk stratification, Postoperative, radiotherapy

The systematic review followed PRISMA 2020 guidelines and searched PubMed, ProQuest and Google Scholar for English-language research published from January 2019 through December 2024. The protocol was registered in PROSPERO in January 2025 under CRD42025632573. Three reviewers independently selected studies, extracted data and assessed the evidence against predefined inclusion criteria, while a fourth reviewer verified their assessments and resolved discrepancies. Eligible studies examined miR-155 expression in patients with cancer who received radiation, chemotherapy, multidrug treatment or combination treatment and reported relevant clinical outcomes. Laboratory, animal, computational, simulation and other preclinical studies were excluded, as were articles without patient data. Studies also had to report survival outcomes according to the therapeutic regimen, narrowing the review to evidence connecting expression with care delivered to patients rather than an assessment of miR-155 as a treatment itself.

The initial search returned 248,057 records: 169,989 from Google Scholar, 77,918 from ProQuest and 150 from PubMed. The reviewers removed 426 duplicates and screened the remaining records by title and abstract, after which 97 articles were assessed in full text. Seventy-eight were excluded, including 32 without validation of miR-155, 26 without therapy-based analyses in patients, 18 without clinical outcomes linked to miR-155 or with insufficient data, and two simulation or machine-learning papers without patient data. Nineteen studies were eligible. Together, the reports comprised 1,640 patient samples, 230 healthy controls and data from 701 patients in two Gene Expression Omnibus datasets. Two publications analyzed the same underlying diffuse large B-cell lymphoma cohort, so they did not provide independent replication. Eleven studies were classified as high quality on the Newcastle-Ottawa Scale, seven were rated moderate to high, and one was rated moderate; none was classified as low quality.

MiR-155 is encoded by the miR-155 host gene, or miR-155HG, and belongs to a precursor family that produces mature miRNAs known as miR-155-5p and miR-155-3p. The clinical studies reviewed focused on measuring miR-155 expression rather than administering a miR-155-directed treatment. Investigators used quantitative real-time polymerase chain reaction to assess expression in tumor tissue, peripheral blood, serum, plasma, exosomal fractions and bone marrow, with one study examining both tissue and blood. These materials do not necessarily represent the same biological state: tissue measurements reflect the local tumor environment, whereas circulating and exosomal measurements capture systemic or extracellular pools. The lack of consistent reporting further complicated interpretation. Sixteen of the 19 studies referred only to “miR-155” without identifying the mature strand, while three explicitly evaluated miR-155-5p.

Four studies reported higher miR-155 expression in treatment-resistant patients. In pediatric acute lymphoblastic leukemia, elevated bone-marrow expression was associated with poor response to induction chemotherapy, residual disease and relapse-related clinical characteristics. In HER2-positive breast cancer, increased miR-155 in serum exosomes was associated with resistance to trastuzumab-containing neoadjuvant therapy, poorer treatment outcomes, shorter progression-free survival and shorter event-free survival. In diffuse large B-cell lymphoma, exosomal miR-155 distinguished patients with refractory or relapsed disease from those who responded to R-CHOP treatment, although the same study did not find an equivalent association in plasma. In gastric diffuse large B-cell lymphoma, higher tissue expression was associated with resistance to Helicobacter pylori eradication therapy. These resistance-associated findings spanned bone marrow, serum, exosomes and tumor tissue, but no resistance association was reported for radiotherapy or immunotherapy in the reviewed evidence. The pattern was therefore concentrated mainly in chemotherapy, targeted-therapy and immunochemotherapy settings rather than being uniform across treatment modalities.

Other studies pointed in the opposite direction. Analyses of patient-derived samples and public lymphoma datasets linked elevated miR-155 after R-CHOP treatment to favorable response and improved survival in germinal center B-cell-like diffuse large B-cell lymphoma, but not consistently in the activated B-cell-like subtype. In pediatric acute lymphoblastic leukemia, one study reported an association between miR-155-5p and favorable early prednisone response, while another associated elevated expression with suboptimal response. These contrasting results indicate that the same expression pattern may carry different clinical meanings in different diseases and treatment settings. The DLBCL findings provide the clearest example of molecular-subtype dependence: higher tissue miR-155 was linked to a favorable outcome in germinal center B-cell-like disease, while elevated exosomal miR-155 was associated with refractory or relapsed disease in another cohort. Neither the direction of the association nor the choice of biological specimen can therefore be assumed to transfer directly from one clinical context to another.

Survival results were also divided. Four studies reported favorable survival associations, four reported adverse associations, one produced mixed or endpoint-dependent findings, and one found no significant difference in overall or progression-free survival. Nine did not perform a miR-155-specific survival analysis. Higher expression was associated with longer overall or progression-free survival in selected germinal center B-cell-like lymphoma and breast cancer cohorts, including triple-negative breast cancer, and with longer disease-free survival in a breast cancer study. Conversely, adverse associations with shorter progression-free, event-free or overall survival appeared in selected lymphoma, lung cancer and breast cancer settings, particularly during chemotherapy or targeted treatment. The same study did not always produce the same relationship across endpoints. In HER2-positive breast cancer, for example, elevated exosomal miR-155 was associated with poorer event-free and progression-free survival but not a statistically significant difference in overall survival. In non-small cell lung cancer treated with platinum-based chemotherapy, higher circulating miR-155 was associated with poorer overall survival, although it was not significantly associated with treatment response or progression-free survival.

Clinical and methodological heterogeneity complicates the interpretation of the evidence. The studies differed in cancer and disease subtype, patient characteristics, therapy, sample type, timing of collection, endpoint definitions and follow-up duration. Six of the 19 studies enrolled 55 or fewer participants, including one with only 10 patients, which can reduce statistical precision and make results more susceptible to random variation. Most of the evidence was observational, and adjustment for potential confounding was inconsistent: nine studies received the maximum comparability score on the Newcastle-Ottawa Scale, eight received one star and two received none. Prospectively collected clinical samples were also mixed with secondary analyses of public molecular datasets. Several studies used a cross-sectional design or collected specimens at different stages of care, limiting the ability to determine whether altered miR-155 preceded or followed response, resistance or progression. Treatment resistance, early response, progression-free survival, event-free survival, disease-free survival and overall survival were treated as distinct endpoints, and differences in follow-up further limited direct comparisons. Most treatment-linked associations also rested on a single study rather than independent replication.

The review does not establish miR-155 as either a clinically usable biomarker or a therapeutic target. No included study evaluated the efficacy of a miR-155-directed intervention in patients, and the available evidence was insufficient to support a universal predictive or prognostic role across cancers. The authors argue for larger prospective multicenter studies with clearly defined patient subgroups, consistent treatment and response criteria, sequential sampling and independent validation. Standardizing specimen collection, RNA extraction, normalization and quantification is also essential, as is explicitly distinguishing miR-155-5p or miR-155-3p from measurements reported only as miR-155. The evidence supports further study of miR-155 as a potentially useful, context-specific marker, but not routine clinical interpretation or treatment decisions based on its expression. Important limitations remain, including the restricted five-year publication window, the use of only three bibliographic sources, the small number of studies for several cancers and the absence of clinical efficacy evidence for interventions directed at miR-155.

Subject of Research: Clinical associations between miR-155 expression and cancer treatment outcomes

Article Title: A systematic review on the possible role of microRNA-155 in cancer treatment

Article References: Ravichandran, S. N., Banerjee, A., Parnigotto, P. P., Pathak, S., & Barbon, S. (2026). A systematic review on the possible role of microRNA-155 in cancer treatment. Frontiers in Pharmacology, 17, Article 1885427. https://doi.org/10.3389/fphar.2026.1885427

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1885427

Keywords: microRNA-155, cancer biomarkers, treatment resistance, treatment response, survival outcomes, systematic review, clinical studies, cancer biology, systematic, review, possible, role

The retrospective study, led by Malia Brennan and colleagues at the University of Washington and the Fred Hutchinson Cancer Center in Seattle, examined 103 patients diagnosed with HER2-positive de novo metastatic breast cancer between 2011 and 2023. The researchers asked two questions that have divided surgical oncologists for years: which patients in this population actually undergo breast surgery, and does the operation change the trajectory of local and distant disease progression or survival compared with systemic therapy alone?

The answer to the first question was clear. Nearly 43 percent of the cohort—42.7 percent—underwent breast surgery, and the choice was far from random. Patients who received surgery tended to be younger, with a median age at diagnosis of 48 years compared with 56 years among those managed without an operation, although that difference did not reach statistical significance. More telling, the surgery group carried a lower metastatic burden: an average of 1.3 sites of distant disease versus 1.9 sites in the non-surgery group, a difference that was statistically significant. In other words, surgeons and their patients were selecting the operations for those with less extensive spread.

The surgical details reveal how practice has evolved. Among those operated on, 70.5 percent underwent mastectomy and 29.5 percent lumpectomy. Axillary surgery was performed in 72.7 percent of surgical patients, but the mix of procedures shows the influence of modern, less invasive staging: 38.6 percent received a full axillary lymph node dissection, 27.3 percent a sentinel lymph node biopsy, and 6.8 percent a targeted axillary dissection—a technique that allows de-escalation of surgery after effective systemic treatment. The high rate of axillary intervention in a metastatic setting underscores how thoroughly the regional nodes were still being evaluated, even when distant disease was present.

Local disease progression emerged as a key selection factor. Before surgery, 39 percent of the surgical group had exhibited local progression at the primary site, compared with 23.5 percent of the non-surgery group—a difference that approached significance. This suggests that uncontrolled disease in the breast itself was one of the triggers pushing clinicians toward operative management. Yet after the operation, the tables turned: only 17.1 percent of surgical patients experienced subsequent local progression, versus 23.5 percent of those treated with systemic therapy alone, a difference that was not statistically significant. Surgery, in this dataset, did not decisively outperform modern drug therapy at controlling the primary site.

The survival signal, however, was dramatic. After adjusting for age, sites of metastases, and the number of metastatic sites in Cox proportional hazards models, patients who underwent breast surgery had significantly improved overall survival, with a hazard ratio of 0.33—meaning roughly a two-thirds reduction in the risk of death—compared with those treated without surgery. Kaplan-Meier analyses supported the same conclusion. On its face, that is the kind of result that could reshape guidelines overnight.

But the authors themselves urge restraint, and the statistical architecture of the study explains why. This was a single-institution retrospective review, not a randomized trial. Logistic regression and multivariable adjustment can account for measured confounders such as age and metastatic burden, but they cannot eliminate selection bias—the inherent tendency for healthier, lower-burden patients to be offered surgery in the first place. The very factors that predicted who got the operation, particularly the lower number of metastatic sites, are also factors that independently predict longer survival. The hazard ratio of 0.33 therefore represents an association, not proof of causation, and the authors state explicitly that the significant association between surgery and improved survival must be interpreted with caution.

The study arrives in a field crowded with competing evidence. Randomized trials have tested primary tumor resection in metastatic breast cancer for a decade: the 2015 Lancet Oncology trial by Badwe and colleagues found no survival benefit for locoregional treatment of the primary tumor, while the MF07-01 protocol by Soran and colleagues reported improved survival with surgery in stage IV disease. The EA2108 trial led by Khan and colleagues found that early local therapy for the primary site in de novo stage IV breast cancer did not improve survival overall. More recently, the Japanese JCOG1017 PRIM-BC trial and a 2024 meta-analysis of randomized controlled trials have added further nuance, and a 2025 Cochrane review systematically assessed breast surgery for metastatic breast cancer. Notably, prior analyses specifically focused on HER2-positive stage IV patients in the era of targeted therapy—such as work by Mudgway and colleagues and by Lu and colleagues—have suggested that the subtype may behave differently, which is precisely the niche this new single-institution study addresses.

What makes the HER2-positive question especially compelling is the transformation of the subtype’s prognosis by HER2-targeted therapy. Drugs directed against the human epidermal growth factor receptor 2 have significantly improved survival in de novo metastatic HER2-positive breast cancer, converting one of the most aggressive diagnoses into a chronic, manageable condition for many patients. As systemic therapy grows more effective, the calculus around local interventions shifts: if the drugs can hold distant disease at bay for years, the question of whether removing the breast adds incremental benefit—or merely risk—becomes empirically testable rather than doctrinal. The Seattle data suggest that in carefully selected patients with limited metastatic burden, surgery is being deployed, and that its association with survival deserves rigorous prospective testing.

The findings also intersect with a parallel movement in early-stage disease: trials such as those led by Kuerer and colleagues have explored eliminating breast surgery entirely for exceptional responders to neoadjuvant systemic therapy, showing that as drug treatment improves, the role of the scalpel is being renegotiated in both directions—expanded for some metastatic patients, withdrawn for some early-stage ones. For now, the practical takeaway for patients with HER2-positive de novo metastatic breast cancer is that surgery remains an option on the table, most often pursued in those with fewer sites of metastatic spread and uncontrolled local disease, and that the apparent survival advantage associated with the operation must await randomized evidence before it can be prescribed with confidence. The study was approved by the University of Washington Research IRB Committee, and the authors declare no competing interests or external funding.

Subject of Research: Medicine & Public Health

Article Title: Surgical management in HER2 + de novo metastatic breast cancer: disease progression and survival

Article References: Brennan, M., Javid, S. H., Flanagan, M. R., Schmicker, R., Gwin, W. R., Fleuret, S., & Palmquist, E. (2026). Surgical management in HER2 + de novo metastatic breast cancer: disease progression and survival. Breast Cancer Research and Treatment, 220(1), Article 7. https://doi.org/10.1007/s10549-026-08108-y

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08108-y

Keywords: breast cancer, HER2-positive, metastatic breast cancer, surgical oncology, de novo stage IV, systemic therapy, survival outcomes, selection bias, Surgical, management, HER2, novo

The China Pancreas Data Center, known as the CPDC, is a national multi-center online registration system that was initiated with the support of the Chinese Pancreatic Surgery Association, the Chinese Society of Surgery, and the Chinese Medical Association. Its purpose is straightforward: to collect standardized, prospectively entered data on pancreatic surgery from hospitals across China so that practice can be benchmarked, outcomes can be compared, and quality improvement initiatives can be grounded in evidence rather than anecdote. The newly published annual report represents a substantial step toward that goal, aggregating perioperative and survival outcomes for a patient volume that few single institutions anywhere in the world could hope to match.

The demographic and clinical profile of the 6,297 patients reflects the typical presentation of pancreatic cancer in a real-world setting. The median age at surgery was 64 years, and men outnumbered women with a male-to-female ratio of 1.2 to 1. Abdominal pain and jaundice emerged as the most common symptoms prompting diagnosis, a pattern consistent with the biology of the disease, which often remains silent until tumors grow large enough to cause obstruction or invade surrounding structures. Roughly 62.6 percent of patients presented with tumors located in the head or neck of the pancreas, the anatomical region where cancers most frequently compress the bile duct and where surgical resection, in the form of a pancreaticoduodenectomy, is among the most technically demanding operations in abdominal surgery.

One of the most closely watched metrics in modern pancreatic surgery is the adoption of minimally invasive techniques. Laparoscopic and robotic approaches have been promoted for their potential to reduce blood loss, shorten hospital stays, and speed recovery, but their role in cancer surgery depends on achieving oncological equivalence with open operations. In this national cohort, minimally invasive surgery was performed in 30.4 percent of cases, a figure that aligns with international benchmarks from high-volume pancreatic centers in Europe, North America, and East Asia. The conversion rate from minimally invasive to open surgery was 24.9 percent, a statistic that underscores the technical complexity of pancreatic resections and the importance of careful patient selection and surgeon experience in determining which approach is appropriate.

Systemic therapy played a prominent role in the treatment pathways captured by the registry. The predominant neoadjuvant and adjuvant chemotherapy regimen was nab-paclitaxel combined with gemcitabine, a doublet that has become a standard backbone for perioperative treatment of pancreatic cancer in guidelines around the world. The use of chemotherapy before and after surgery reflects a broader shift in the field, driven by clinical trials showing that multimodal treatment can improve survival even when the tumor is technically resectable. The CPDC data suggest that this paradigm has been widely integrated into Chinese surgical practice during the study period.

The safety metrics reported by the CPDC are the headline finding of the study and the numbers most likely to attract international attention. In-hospital mortality was just 0.6 percent, 30-day mortality was 1.2 percent, and 90-day mortality was 3.1 percent. For an operation historically associated with perioperative mortality rates in the double digits, these figures represent the cumulative result of decades of progress in surgical technique, perioperative care, centralization of complex surgery, and standardized postoperative management. Equally important for long-term prognosis, the one-, two-, and three-year overall survival rates reached 75.8 percent, 53.3 percent, and 42.0 percent, respectively. The authors state that these survival figures align with established benchmarks from international high-volume pancreatic centers, positioning China’s surgical outcomes for pancreatic cancer within the range of the best-performing systems worldwide.

Beyond the clinical numbers, the report offers a revealing portrait of how complex cancer surgery is organized across China’s vast and regionally uneven healthcare landscape. Nearly 45 percent of patients in the registry traveled across provincial borders to undergo their operations, a striking indicator of how far patients are willing to go to reach a surgeon or center they trust for one of the most complex operations in oncology. The authors attribute this pattern to regional disparities in medical resources rather than to patient preference alone. In advanced medical resource areas such as Beijing and Shanghai, over 99 percent of patients received their treatment locally, meaning that patients in those cities essentially never needed to leave home for surgery. The corollary is that patients in regions with fewer high-volume pancreatic surgery programs must often undertake long journeys to access equivalent care.

This geographic concentration of pancreatic cancer surgery in high-volume specialist centers carries both advantages and challenges. On the one hand, the centralization of complex procedures is widely recognized as a key driver of the low mortality and strong survival outcomes documented in the report, since outcomes in pancreatic surgery are closely tied to institutional volume and multidisciplinary expertise. On the other hand, the concentration creates access barriers for patients in less developed regions and places enormous demand on a limited number of centers. The authors emphasize the need to develop and roll out national-level benchmarks and standardized clinical protocols for pancreatic surgery across China, with the aim of raising the floor of care nationwide while preserving the strengths of the existing high-volume hubs.

The significance of the CPDC report extends beyond the borders of China. Real-world registry data of this scale are rare in pancreatic oncology, where much of the published evidence derives from single-center series, clinical trials with carefully selected populations, or national databases with variable completeness. A registry covering 65 centers and nearly 6,300 patients provides a granular view of who undergoes surgery, how the operations are performed, what perioperative therapies are delivered, and what outcomes result, all within a single standardized framework. For researchers and clinicians internationally, the report offers a benchmark against which other national systems can be compared, and for Chinese institutions it establishes a baseline for measuring the impact of future quality improvement efforts.

Pancreatic cancer accounts for a substantial and rising share of cancer deaths in China, and the demand for surgical treatment is expected to grow as the population ages and diagnostic capacity improves. The CPDC annual data report demonstrates that a coordinated national registry can capture the realities of surgical care at scale, from the adoption of minimally invasive techniques and perioperative chemotherapy to the regional patterns of patient travel and the hard endpoints of mortality and survival. As the registry continues to accumulate data in successive years, it is positioned to serve as an ongoing instrument for auditing performance, identifying gaps between centers, and guiding the standardization of pancreatic surgery across a healthcare system whose scale makes it unlike any other in the world. For the 6,297 patients whose outcomes form the backbone of this report, the findings confirm that pancreatic cancer surgery in China has reached a level of safety and effectiveness comparable to the leading international centers, while also making clear where the next phase of improvement must be directed.

Subject of Research: Real-world surgical outcomes for pancreatic cancer patients in China

Article Title: China reports real-world surgical outcomes for 6,297 pancreatic cancer patients

Article References: China reports real-world surgical outcomes for 6,297 pancreatic cancer patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pancreatic cancer, pancreatic surgery, China Pancreas Data Center, minimally invasive surgery, cancer registry, survival outcomes, Journal of Pancreatology, surgical oncology, China, reports, real-world, surgical

The study, known as COMIT-ANZ, was led by researchers at the University of Melbourne’s Austin Health Precinct together with the Prometheus Transplant Collaborative, spanning hospitals from Queensland to Western Australia and Auckland City Hospital in New Zealand. The team set out to measure clinical outcomes for patients who had undergone liver transplantation either knowingly for cholangiocarcinoma or unknowingly, when the tumour was discovered only after the diseased liver had been removed and examined under the microscope. Their findings carry real weight for a subspecialty that is expanding faster than its evidence base.

Cholangiocarcinoma is a malignancy that arises from the epithelial cells lining the bile ducts, the narrow channels that drain bile from the liver into the intestine. It carries a notoriously poor prognosis, and its behaviour depends heavily on where it sits. Intrahepatic cholangiocarcinoma develops within the liver substance itself, while the majority of extrahepatic tumours are perihilar, clustering at the liver hilum where the bile ducts converge. That anatomical distinction is not merely academic; it determines which transplant pathway a patient can access, because the evidence supporting transplantation differs profoundly between the two sites.

For perihilar tumours that cannot be surgically resected, transplantation is only offered when centres have an established neoadjuvant chemoradiotherapy protocol in place, a strategy pioneered at the Mayo Clinic in which patients receive external beam radiotherapy followed by chemotherapy before the transplant itself. International series report five-year overall survival of roughly 53 to 71 percent for these patients. For very early intrahepatic cholangiocarcinoma, defined as a single tumour smaller than two centimetres in a cirrhotic liver, a growing body of retrospective data has convinced the International Liver Transplant Society to endorse transplantation. The catch, as the COMIT-ANZ authors point out, is that nearly all of the data informing that guidance came from North American, Asian and European centres, leaving the applicability to Australia and New Zealand genuinely unknown.

To close that gap, the researchers mined the Australia and New Zealand Liver and Intestinal Transplant Registry, the national registry that has captured transplant activity since the region’s programmes began in 1986. Local transplant unit leads re-identified eligible recipients and entered de-identified clinical data into a REDCap database, capturing demographics, transplant details, explant histology, patient and graft survival, recurrence status and cause of death. The primary outcome was five-year overall survival, with recurrence-free survival as a secondary measure. In total, 64 adult patients were identified who had been transplanted for either known or incidentally detected cholangiocarcinoma or a mixed hepatocellular-cholangiocarcinoma, a rare biphenotypic tumour carrying histological features of both parent cancers.

The demographic profile of these patients was telling. Three-quarters were male, the median age at transplant was 55 years, and the median MELD score, the laboratory measure of liver disease severity used to prioritise waiting-list patients, was 14. Perhaps the most consequential finding was the timing of diagnosis: 75 percent of these tumours were detected incidentally on explant histology, meaning neither the patient nor the surgical team knew the cancer was there before the transplant. Only 16 patients, one quarter of the cohort, were knowingly transplanted for cholangiocarcinoma, and most of those had underlying primary sclerosing cholangitis, an inflammatory condition of the bile ducts that predisposes patients to perihilar tumours.

The survival figures tell a nuanced story. Across all 64 patients, the five-year overall survival was 47 percent, with recurrence-free survival of 60 percent, figures that sit well below the 83 percent five-year survival for liver transplantation in the region overall and the 79 percent for hepatocellular carcinoma. But the all-comer number conceals the real signal. When the researchers stratified by tumour size, patients with intrahepatic cholangiocarcinomas smaller than two centimetres achieved five-year overall and recurrence-free survival of 80 percent, squarely in line with the international data underpinning the current ILTS guidance. By contrast, patients with perihilar tumours fared far worse, with five-year overall survival of just 31 percent and recurrence-free survival of 40 percent, significantly inferior to the intrahepatic group.

The statistical analysis sharpened these contrasts further. Univariate Cox regression identified age, known pre-transplant tumours, mixed histological type and poorly differentiated tumours as factors associated with poorer overall survival. When variables with p values below 0.20 were carried into a multivariate model, only one factor remained independently significant: poorly differentiated tumours, which carried a hazard ratio of 4.78 for death compared with better-differentiated cancers. The authors suggest this finding could eventually inform pre-transplant decision making, since a biopsy demonstrating poorly differentiated cholangiocarcinoma might steer a patient toward a different treatment path, though they caution that the role of pre-operative biopsies in risk stratification requires further study.

The mixed hepatocellular-cholangiocarcinomas deserve particular attention, because clinical outcomes after transplantation for these tumours have never been clearly established. All 17 mixed tumours in this cohort were detected incidentally on explant histology, and none were knowingly transplanted, a reflection of how difficult these cancers are to diagnose before surgery. Radiologically, mixed tumours cannot be reliably distinguished from pure hepatocellular carcinoma, and neither biopsies nor tumour markers such as alpha-fetoprotein and CA19-9 carry sufficient sensitivity, since elevated levels of both may reflect the biphenotypic nature of the neoplasm. Yet the survival data was unexpectedly reassuring: five-year overall survival for the mixed group was 68 percent, significantly better than the 51 percent for pure cholangiocarcinomas, and comparable to the 70 percent reported in a multi-centre American study of 67 patients transplanted for mixed tumours within Milan criteria.

The authors are candid about the limitations of their work. The study is retrospective, spanning an era in which clinical practice has changed enormously, and not every data point was available for every patient, which affected the completeness of the statistical analysis. Significant heterogeneity also exists within the cohort, mixing knowingly transplanted perihilar and intrahepatic tumours with incidental discoveries and the mixed histological subtype. Still, the central conclusion stands: the international guidance on very early intrahepatic cholangiocarcinoma does apply to Australia and New Zealand, and patients transplanted with cirrhosis and tumours under two centimetres can expect excellent five-year survival. As transplant oncology expands and demand for donor organs grows, audits like this one provide the regional evidence needed to decide, ethically and practically, who should receive a scarce and precious liver.

Subject of Research: Liver transplantation outcomes for cholangiocarcinoma and mixed hepatocellular-cholangiocarcinoma in Australia and New Zealand

Article Title: COMIT-ANZ: an audit of cholangiocarcinoma and mixed hepatocellular carcinoma-cholangiocarcinoma outcomes for patients undergoing liver transplantation in Australia and New Zealand

Article References: Riddiough, G. E., Hall, K., Byrne, M., Brown, K., Kilburn, D., Goh, S. K., Marshall-Webb, M., Pulitano, C., Chan, K., Philipoff, A., Nazaar, A., & Lee, E. (2026). COMIT-ANZ: an audit of cholangiocarcinoma and mixed hepatocellular carcinoma-cholangiocarcinoma outcomes for patients undergoing liver transplantation in Australia and New Zealand. Frontiers in Transplantation, 5, Article 1856922. https://doi.org/10.3389/frtra.2026.1856922

Image Credits: AI Generated

DOI: 10.3389/frtra.2026.1856922

Keywords: liver transplantation, cholangiocarcinoma, transplant oncology, mixed hepatocellular-cholangiocarcinoma, intrahepatic cholangiocarcinoma, survival outcomes, Australia New Zealand, ILTS guidance, COMIT-ANZ, audit, mixed, hepatocellular

The study, published in Pathology and Oncology Research, drew on the National Health Insurance Fund, a claims database that covers nearly the entire Hungarian population and records diagnoses, reimbursed prescriptions, medical interventions, and demographic data. Researchers led by Krisztina Bogos of the National Korányi Institute of Pulmonology in Budapest identified 8,104 patients with extensive-stage small cell lung cancer who received first-line etoposide-platinum chemotherapy between 2013 and 2022. To isolate true extensive-stage disease, the team excluded patients who had received concomitant chemoradiotherapy or curative thoracic surgery, treatment patterns characteristic of limited-stage disease, and consulted available histology results to confirm lung cancer pathology. The resulting cohort is one of the largest national datasets of its kind in Central Europe and provides a national benchmark for outcomes in the era before immunotherapy became widely available in Hungary.

The epidemiological findings reveal shifting demographics that mirror broader smoking trends across Central and Eastern Europe. Nearly half of all patients, 47.9 percent, were aged 60 to 69 years at diagnosis, but the age distribution gradually moved toward older groups over the decade. In 2013, 22 percent of patients were aged 70 or above; by 2022, that proportion had risen to 35.1 percent, while the share of patients under 50 declined from 5.14 percent to 3.75 percent. The gender gap also narrowed steadily. Men accounted for 53.1 percent of cases overall, but the male-to-female ratio evened out from 53.7 versus 46.3 percent in 2013 to an exact 50 versus 50 percent split by 2022, a pattern consistent with the Korányi Bulletin’s documentation of the total lung cancer population shifting from 84 percent male in 1980 to 53 percent male in 2022.

Regional analysis uncovered striking geographic variation in incidence. Using 2022 county population data from the Hungarian Central Statistical Office as a reference, Baranya County recorded the highest incidence at 136.4 cases per 100,000 people, well above the national average of 82.7 per 100,000. The authors note that Baranya’s mining history, including the operation of a uranium mine between 1957 and 1997, may hypothetically have contributed to this pattern through historical environmental exposures, and several studies have reported associations between air pollution and small cell lung cancer risk. However, they caution that these interpretations remain speculative and that no causal relationship can be established from the present data.

Treatment patterns documented a clear shift in chemotherapy practice. Carboplatin-based regimens dominated throughout the study period, accounting for 71 percent of cases overall, and the carboplatin-to-cisplatin ratio moved from 63 versus 37 percent in 2013 to 87 versus 13 percent in 2022, reflecting the gradual replacement of cisplatin with the generally better-tolerated carboplatin. Treatment intensity varied considerably: 46 percent of patients completed two to four cycles of etoposide-platinum, 34 percent underwent five or more cycles, and 20 percent received only a single cycle, a halt in treatment that likely reflects chemotherapy intolerance or rapid clinical deterioration. Radiotherapy was frequent, with 38.4 percent of the cohort undergoing it at some point, most commonly as a short course of one to two cycles, while only 4.7 percent received long-course thoracic radiotherapy, which generally signals curative-intent sequential chemoradiotherapy associated with limited-stage disease.

Subsequent therapy was common among progressing patients. Overall, 38.7 percent of the full cohort received second-line treatment, and among those patients, etoposide-platinum rechallenge was the most widespread approach, used in 49.7 percent of subsequent-therapy cases. For platinum-refractory patients, cyclophosphamide-epirubicin-vincristine combinations with or without etoposide accounted for 28.1 percent, followed by topotecan at 17.9 percent, other platinum-based doublets at 1.6 percent, and other agents at 2.7 percent. Approximately 6 percent of patients underwent more than two lines of treatment. These patterns align with standard European practices, in which etoposide-platinum rechallenge is preferred for platinum-sensitive relapsed cases, and with the 2013 ESMO guideline recommending intravenous topotecan and the classical CAV regimen for platinum-refractory patients.

For the efficacy analysis, the researchers narrowed the cohort to 5,576 patients who initiated etoposide-platinum within one year of their first lung cancer diagnosis between 2013 and 2019, enabling at least three years of follow-up. Because the insurance database does not record tumor progression directly, progression-free survival was inferred using time to first subsequent therapy or death as a proxy, a method that may slightly prolong the apparent progression-free interval since a patient’s condition can worsen before a new treatment begins. The results were sobering: median progression-free survival was 6.5 months, with only 52.9 percent of patients remaining progression-free at six months, 19 percent at one year, and 5.2 percent at three years. Median overall survival was 9.3 months, with 69.8 percent of patients surviving the first six months, 37.5 percent at one year, 14.9 percent at two years, and 9.2 percent at three years. Of the 5,576 patients, 94.8 percent either received first subsequent therapy or died within the follow-up period, underscoring how relentlessly this disease progresses despite initial treatment.

A sensitivity analysis excluding the 303 patients who received long-course radiotherapy, designed to reduce potential bias from multimodal therapy and to indirectly exclude curative-intent sequential chemoradiotherapy, confirmed the robustness of the primary findings. In that reduced cohort of 5,273 patients, median progression-free survival was 6.3 months with a six-month rate of 51.8 percent and a three-year rate of 5.0 percent, while median overall survival was 8.9 months with a one-year rate of 35.6 percent and a three-year rate of 8.7 percent. The authors note that the slightly longer progression-free survival observed in their study compared with clinical trials can be attributed to the proxy method, since even short delays between radiologic progression and the initiation of subsequent therapy may extend the measured interval. The shorter overall survival, by contrast, likely reflects that real-world patients do not fit the strict eligibility criteria of phase III trials, which typically require performance status 0 to 1, adequate kidney and liver function, and a life expectancy of at least 12 weeks.

These Hungarian outcomes sit squarely within the range of international real-world evidence. France reported an overall survival of 11.8 months and progression-free survival of 6.1 months in its ESME cohort, while Spain reported overall survival of 8.2 months and progression-free survival of 5 months. The findings also align closely with the chemotherapy control arms of the landmark immunotherapy trials: in CASPIAN, which tested durvalumab added to etoposide-platinum, the control arm had a median progression-free survival of 5.4 months with 12- and 24-month rates of 5.3 and 2.9 percent, and in IMpower133, which tested atezolizumab, the control arm had a median progression-free survival of 4.3 months with a six-month rate of 22.4 percent. The consistency between the Hungarian national data and these trial control arms validates the methodology and confirms that the Hungarian extensive-stage small cell lung cancer population behaves as clinical expectations predict.

The study arrives at a pivotal moment. Immunotherapy combinations with etoposide-platinum were accessible in Hungary only through individual requests from 2022 and became nationally reimbursed in 2024, meaning the accumulation of real-world follow-up data on chemo-immunotherapy will take time. Until then, this analysis stands as a reliable national baseline, complementing international evidence as one of the largest extensive-stage small cell lung cancer cohorts in Europe, against which the impact of chemo-immunotherapy in routine practice can be measured. The authors emphasize that the aggressive nature of the disease and the limited efficacy of chemotherapy-based treatments underscore the need to improve existing first-line and subsequent-line options and to introduce novel therapies. They also call for future studies with extended follow-up that incorporate staging, radiotherapy intent, comorbidities, and progression data, and for an ideal cancer registry with standardized coding practices and structured oncologic variables, so that the next decade of Hungarian data can tell a very different story.

Subject of Research: Health

Article Title: Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022)

Article References: Bogos, K., Bajcsay, A., Gálffy, G., Tamási, L., Pápai-Székely, Z., Sárosi, V., Maráz, A., Pálföldi, R., Horváth, L., Hoffer, J., Szécsényi, S., Kirschner, K., Blasszauer, C., Reibl, D., Komka, I., Ascsillán, A. A., Kemény, L. V., & Ostoros, G. (2026). Extensive-stage small cell lung cancer in Hungary: a real-world analysis (2013–2022). Pathology &amp; Oncology Research, 32, Article 1612491. https://doi.org/10.3389/pore.2026.1612491

Image Credits: AI Generated

DOI: 10.3389/pore.2026.1612491

Keywords: lung cancer, oncology, small cell lung cancer, real-world evidence, survival outcomes, Hungary, chemotherapy, immunotherapy, Extensive-stage, small, cell, lung

The author’s position is notable in this respect. Haliwungan is affiliated with the Department of Islamic Studies at Selamat Sri University in Kendal, Indonesia, rather than with a medical school or children’s hospital. That disciplinary distance may be precisely what allows the poem to frame pediatric medicine in moral and even theological terms. The abstract speaks of compassion, dignity, and collective responsibility as the true measures of civilization, language that belongs more naturally to ethics and religious thought than to biostatistics. The inclusion of such a voice in a research journal suggests an editorial willingness to treat the humanities not as decoration but as a parallel mode of inquiry into the same questions that science addresses with instruments and protocols.

The central paradox the poem identifies deserves careful articulation. Children are, in a strictly biological sense, the most vulnerable members of any human population. Their immune systems are immature, their organs are still developing, their capacity to communicate symptoms is limited, and their futures depend entirely on the decisions of adults. Every pediatrician works daily inside this asymmetry of power and capability. And yet, as the poem insists, children are simultaneously the deepest reservoir of hope that humanity possesses. They embody possibility in a way no adult can; they are the future tense made flesh. To hold both truths at once, that a child is maximally at risk and maximally promising, is the emotional and ethical burden of pediatric care, and it is a burden that clinical literature seldom names directly.

The images the abstract enumerates, neonatal wards, parental devotion, and life-sustaining technologies, map onto the actual geography of modern pediatric medicine. The neonatal intensive care unit is perhaps the most vivid setting in which this paradox plays out. There, infants born at the very edge of viability are sustained by ventilators, incubators, and infusion systems that represent decades of accumulated scientific progress. A generation ago, many of these infants would not have survived their first hours. The technology is genuinely revolutionary, and yet the outcome of any single stay in such a unit remains profoundly uncertain. Parents keep vigil at incubator sides, unable to hold their children, negotiating hope against fear in ways that no monitor can quantify. The poem’s juxtaposition of medical progress with enduring uncertainty captures this lived reality with an economy that a research report cannot achieve.

Parental devotion, the second image named in the abstract, is a subject that pediatric research encounters constantly but rarely theorizes. Studies of family-centered care, parental stress in intensive care settings, and the long-term psychological effects of a child’s hospitalization all document the intensity of the parent-child bond under medical duress. What the poem adds is an acknowledgment that this devotion is not merely a variable affecting outcomes but a moral force in its own right. The parent who keeps watch over a fragile newborn is performing an act of love that predates and exceeds any clinical intervention. Medicine depends on this devotion, cooperates with it, and is often humbled by it. A discipline that treats the family as context can learn something from a poem that treats the family as co-author of the child’s survival.

The poem’s most philosophically ambitious claim is its reframing of survival as a moral achievement rather than a clinical outcome. In the language of research, survival is an endpoint: a child is discharged, a follow-up visit is scheduled, a Kaplan-Meier curve extends a little further. The poem asks readers to see the same event differently. When a child who might have died instead lives, something has been achieved not only by the technology and the clinicians but by a whole civilizational arrangement, the allocation of resources, the training of specialists, the social willingness to spend enormous effort on its smallest members. Survival, in this view, is evidence about who we are, not merely about what our machines can do. This is a claim that resonates with long traditions in moral philosophy, which have often used the treatment of the weakest as a test of a society’s character.

It is worth considering why such a message arrives in poetic form rather than as an editorial or a commentary. Poetry operates by juxtaposition and image rather than by argument and evidence, and this makes it suited to expressing tensions that prose analysis tends to resolve prematurely. The tension between progress and uncertainty, between vulnerability and hope, is not a problem to be solved but a condition to be inhabited. Clinicians inhabit it daily; researchers encounter it whenever a promising therapy produces mixed results; parents live inside it for the duration of a child’s illness. A poem can hold these opposites in suspension without pretending that one will eventually cancel the other. That capacity may be why the genre has historically accompanied medicine, from ancient healing rituals to contemporary narrative medicine programs that train clinicians to read literature as a way of deepening their attention to patients.

The poem’s insistence that every child’s heartbeat quietly reshapes our collective future also invites reflection on the demographics and economics of child health. Globally, the majority of childhood deaths occur in settings with limited resources, from preventable causes that affluent countries largely eliminated decades ago. The moral achievement the poem describes is therefore unevenly distributed: whether a child’s survival counts as a routine clinical outcome or a small miracle depends heavily on where that child is born. Pediatric research as a field has increasingly attended to these inequities, and a poem published in an international journal, written by an Indonesian scholar, quietly underscores that the questions of dignity and responsibility it raises are global ones. The heartbeat that reshapes the future belongs to children in Kendal and in Kansas City alike, and civilization is measured, the poem suggests, by how all of them are cared for.

There is also something instructive in the poem’s restraint. It does not celebrate scientific achievement alone, as the abstract explicitly states. This restraint distinguishes it from a triumphalist narrative in which the history of pediatrics is a story of steady conquest over disease. The reality is more complicated. Advances in neonatology have created categories of survivors with ongoing medical and developmental needs; technologies that sustain life raise questions about the quality and meaning of the lives sustained; and every intervention occurs within finite systems that must ration attention and resources. A mature account of pediatric progress holds gratitude and ambivalence together. The poem models that maturity, honoring the ventilators and the wards while refusing to let them exhaust the meaning of what happens in those spaces.

The publication details of the piece, received in late July, accepted in mid-August, and published in early September of 2026, indicate a swift editorial path, suggesting that the journal recognized the piece as timely rather than treating it as a curiosity. The author declares no competing interests and received no specific funding, which is unremarkable for a poem but worth noting as a reminder that some contributions to medical literature arise from vocation rather than from the grant economy that shapes most research. The work stands outside the usual incentive structures, and perhaps for that reason it can say things that funded studies cannot.

For readers of the journal, the practical significance of such a publication may lie in what it offers clinicians and researchers as they return to their routine work. Burnout and moral distress are well-documented hazards of pediatric practice, particularly in intensive care settings where clinicians repeatedly accompany families through uncertainty and loss. Literature has long served as a resource for meaning-making in such circumstances, and a poem that dignifies the emotional labor of pediatric care can function as a form of professional sustenance. It reminds the researcher poring over datasets that behind every data point is a heartbeat, and it reminds the clinician that the vigil at the incubator is witnessed and understood.

Finally, the poem’s title deserves a last reflection. Revolutions are usually imagined as loud, sudden, and public. A quiet revolution is something else: incremental, cumulative, and easily overlooked. Child survival is exactly such a revolution. Over the past century, the near-miraculous has become routine, so gradually that the miracle is often forgotten. Each discharged newborn, each recovered toddler, each child who grows up to parent children of their own constitutes a small, quiet transformation of the human story. By naming this revolution, the poem performs a service that data alone cannot: it restores to view the moral grandeur of an enterprise that, in its daily practice, can seem merely technical. The heartbeat of a child, the poem insists, is not only a vital sign. It is a sign of what humanity, at its best, chooses to be.

Subject of Research: A child’s quiet revolution

Article Title: A child’s quiet revolution

Article References: Haliwungan, A. I. (2026). A child’s quiet revolution. Pediatric Research. https://doi.org/10.1038/s41390-026-05449-8

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05449-8

Keywords: pediatric care, pediatric research, medical humanities, neonatal intensive care, child health, compassion in medicine, bioethics, survival outcomes, pediatric medicine, healthcare ethics, childhood illness, medical technology

The research team, headed by Gobi Hariyanayagam Gunasekaran and colleagues, registered their protocol with PROSPERO and searched five major databases — Scopus, Web of Science, MEDLINE, CINAHL, and Cochrane — from inception to May 2026. From an initial pool of 4,262 citations, 95 studies met the inclusion criteria, and 30 were ultimately pooled in the meta-analysis. The team used a random-effects model to account for the expected heterogeneity across diverse health systems, patient populations, and treatment eras. Their primary outcomes were adherence rates and overall survival, with subgroup analyses by tumour site and disease stage.

The headline finding is nuanced. Across all tumour sites, adherence to clinical practice guidelines was associated with a survival benefit that did not reach statistical significance — a pooled risk ratio of 0.90 with a 95 percent confidence interval of 0.67 to 1.20. The heterogeneity was extreme, with an I-squared value of 99.78 percent, meaning nearly all of the variation between studies reflected genuine differences in populations, interventions, and measurement approaches rather than chance. But when the researchers drilled down by tumour stage, a clearer picture emerged.

For Stage II colon cancer, guideline adherence was associated with a significant survival advantage, with a risk ratio of 0.58 and a confidence interval of 0.34 to 0.99. Stage III colon cancer showed an equally compelling signal, with a risk ratio of 0.58 and a confidence interval of 0.41 to 0.80. In both cases, the confidence intervals excluded the null value of 1.0, indicating that patients whose care followed the guidelines had meaningfully better odds of survival. For Stage II-III rectal cancer, however, the trend toward improved survival was present but did not reach statistical significance, with a risk ratio of 0.59 and a confidence interval of 0.34 to 1.03. The lower heterogeneity in the rectal cancer subgroup — an I-squared of 35.53 percent — suggests the findings there were more consistent across studies, even if the pooled effect was less definitive.

Why the difference between colon and rectal cancer? The authors point to the complexity of rectal cancer management, which typically involves multimodality treatment — surgery, radiotherapy, and chemotherapy in various sequences — where deviations from guidelines may reflect clinical judgment about individual patient factors rather than simple noncompliance. The heterogeneity in colon cancer subgroups, by contrast, was extremely high, reflecting the wide range of health systems, time periods, and adherence definitions across the included studies. This is a critical caveat: the meta-analysis pools observational data, not randomized trials, so the associations cannot be interpreted as definitive causal proof.

Perhaps the most striking findings concern who is most likely to fall outside the guidelines. Non-adherence was consistently more common among patients of advancing age and those facing structural disadvantage — lower socioeconomic strata, non-white ethnicity, and treatment in non-accredited facilities. These are not random variations; they map onto documented patterns of structural inequity in cancer care delivery. The authors frame this as a systemic issue rather than a matter of individual clinician judgment, noting that disparities in guideline adherence reflect structural and systemic disparities in how cancer care is organized and delivered.

The evidence base underpinning this review draws on decades of real-world data. Studies from the Netherlands, Canada, Australia, the United States, Spain, France, Japan, and Sub-Saharan Africa all contributed to the pooled analysis, spanning treatment patterns from the 1990s through the 2020s. Earlier work, such as a 1997 French study published in JAMA, demonstrated that clinical guidelines programs could improve outcomes in breast and colon cancer, while more recent analyses from the National Cancer Database and SEER-Medicare have refined our understanding of how age, comorbidity, and hospital characteristics influence adherence. The current review synthesizes this entire body of evidence into a single, coherent picture.

The technical rigor of the meta-analysis is worth noting. The researchers used the CASP checklist for cohort studies to assess quality, applied VanderWeele’s methods for converting odds ratios and hazard ratios to risk ratios, and employed Duval and Tweedie’s trim-and-fill method alongside Egger’s regression to assess publication bias. They used Comprehensive Meta-Analysis software for the pooled analyses. The extremely high heterogeneity values — approaching 100 percent in the overall analysis — are a signal that the individual studies differed substantially in their populations, interventions, and outcome definitions, which the authors acknowledge as a limitation of pooling observational data across such diverse settings.

The implications for clinical practice and health policy are significant. The findings underscore that simply publishing guidelines is insufficient; health systems must actively address the barriers that prevent adherence, particularly among high-risk populations. The authors call for interventions targeting the structural and systemic factors that contribute to non-adherence — from hospital accreditation status to socioeconomic support for patients navigating complex treatment pathways. Implementation science frameworks, patient navigation programs, and multidisciplinary team approaches have all shown promise in prior research, and this review provides the quantitative evidence base to justify scaling such interventions.

Ultimately, this study reframes guideline adherence not as a binary measure of clinical quality but as a window into the equity of cancer care delivery. The survival benefits of following evidence-based recommendations are real for Stage II and III colon cancer, but they are not distributed equally. As colorectal cancer incidence continues to rise globally — with projections suggesting a substantial increase in burden through 2040 — ensuring that guideline-concordant care reaches all patients, regardless of age, ethnicity, socioeconomic status, or the type of facility where they receive treatment, will be one of the defining challenges of modern oncology.

Subject of Research: Disparities in adherence to colorectal cancer clinical practice guidelines and their association with survival outcomes

Article Title: Exploring disparities in adherence to colorectal cancer clinical practice guidelines and associated survival outcomes: a systematic review and meta-analysis

Article References: Gunasekaran, G. H., Ibrahim, B., Saleem, F., & Shabaruddin, F. H. (2026). Exploring disparities in adherence to colorectal cancer clinical practice guidelines and associated survival outcomes: a systematic review and meta-analysis. Supportive Care in Cancer, 34(9), Article 923. https://doi.org/10.1007/s00520-026-11134-7

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11134-7

Keywords: colorectal cancer, clinical practice guidelines, guideline adherence, survival outcomes, health disparities, meta-analysis, systematic review, colon cancer, rectal cancer, health equity, oncology, adjuvant chemotherapy

Thin melanoma, generally defined as an invasive melanoma measuring one millimeter or less in Breslow thickness, carries an excellent prognosis when caught early, and most patients with these lesions are cured with wide local excision alone. That is precisely why the new findings are striking. If even patients with thin, apparently low-risk melanomas face unequal survival odds depending on where they live, it suggests that the mechanisms driving melanoma deaths operate well before and well after the moment of diagnosis, shaped by access to care, follow-up surveillance, and broader social conditions rather than tumor biology alone.

The study, led by Maria Kaltchenko of the Department of Dermatology at Johns Hopkins and supervised by Joel Sunshine and Kristin Bibee, took the form of a retrospective cohort study, a design in which investigators look backward at existing medical records to compare outcomes across groups defined by an exposure of interest. In this case, the cohort consisted of patients referred to a high-risk specialty clinic, a population that is already under heightened surveillance for skin cancer. The exposure was area deprivation, measured not by individual income or education but by a composite index attached to the patient’s residential neighborhood.

Area deprivation indices have become one of the most widely used tools in health disparities research. Rather than relying on self-reported income, which is frequently missing from medical records and difficult to verify, these indices aggregate census-derived variables such as household income, unemployment, education, and housing quality for the small geographic area in which a person lives. The result is a percentile score that situates each patient’s neighborhood on a spectrum from least to most disadvantaged. The approach was popularized in part by the Neighborhood Atlas project described in the New England Journal of Medicine byKind and Buckingham, which made neighborhood disadvantage metrics freely accessible so that researchers and clinicians could link them to health records. The appeal is straightforward: a single, reproducible number captures a web of social conditions, from transportation access and food insecurity to housing instability and the local availability of medical services.

Why would neighborhood deprivation matter for a cancer that is, in principle, highly survivable? The answer likely lies in the full arc of the disease, from prevention to long-term follow-up. Melanoma detection depends on skin awareness, access to dermatologic evaluation, and the ability to act on a suspicious lesion quickly. Patients in deprived neighborhoods may face barriers at every one of these steps: fewer dermatologists nearby, less flexibility to take time off work for appointments, lower rates of skin self-examination, and delayed presentation once a lesion is noticed. After diagnosis, surveillance matters enormously. Patients with a history of melanoma require regular full-body skin examinations, and recurrences or second primary melanomas caught early are far more treatable than those discovered late. Missing follow-up appointments, whether because of cost, transportation, or competing life demands, can translate into later-stage detection of new disease.

The Johns Hopkins team chose to study a high-risk referral cohort for a specific methodological reason. Patients referred to specialty melanoma and high-risk skin cancer clinics typically receive uniform, protocolized care: standardized follow-up intervals, systematic total-body skin examinations, and consistent patient education. By studying outcomes within such a cohort, investigators can partly neutralize the confounding effect of variable treatment quality. If deprivation is still associated with melanoma-specific death even among patients receiving comparable specialist care, that points toward factors that operate outside the clinic, in the periods before diagnosis and between visits, or in differences in comorbid health, immune function, and health behaviors that cluster with socioeconomic disadvantage.

Melanoma-specific mortality is a deliberately precise endpoint. Rather than counting deaths from any cause, which would obscure the picture in an older cohort where cardiovascular disease and other cancers are common, researchers track deaths attributable to melanoma itself. This distinction matters because prior work has shown that patients with thin melanomas are actually more likely to die of something other than their melanoma. A large study by Lo and colleagues published in JAMA Dermatology in 2024 examined the risk of death due to melanoma versus other causes in patients with thin cutaneous melanomas and highlighted this competing-risk landscape. Any analysis of melanoma-specific death in a thin melanoma population must therefore grapple with the fact that melanoma deaths, while devastating, are statistically the minority of deaths in this group, which demands careful statistical handling and large, well-characterized cohorts.

The broader literature on socioeconomic status and cancer outcomes provides consistent context for the new study. Research published in JAMA Network Open by Cheng and colleagues in 2021 found that both neighborhood-level and individual-level socioeconomic disadvantage were associated with worse survival across multiple common nonmetastatic cancers, suggesting that the effect is not unique to melanoma. In dermatology specifically, Cortez, Vasquez, and Wei reviewed the impact of demographics, socioeconomics, and health care access on melanoma outcomes in the Journal of the American Academy of Dermatology, and Rosenthal and colleagues documented disparities in melanoma-specific mortality by race, ethnicity, socioeconomic status, and health care system factors. What the Johns Hopkins study adds is a focused look at the thin melanoma population, a group in whom tumor biology should confer a strong survival advantage, and an assessment of whether neighborhood deprivation erodes that advantage even within a high-risk referral setting.

The implications of the research reach beyond academic curiosity. If area deprivation independently predicts melanoma death, then the conventional risk stratification used in clinics, which relies almost entirely on tumor thickness, ulceration, mitotic rate, and patient age, is incomplete. Incorporating neighborhood disadvantage metrics into risk assessment could identify patients who warrant closer surveillance, more intensive patient education, or structured navigation services to ensure they actually attend follow-up visits. Health systems could use deprivation scores to allocate outreach resources, scheduling support, and telehealth options toward the patients least likely to otherwise maintain surveillance. At the policy level, the findings feed into a growing recognition that zip code can be as consequential for cancer survival as genetic code, and that interventions targeting the social determinants of health are, in a meaningful sense, cancer interventions.

The study also underscores how much remains to be learned about why thin melanomas, which should almost never be fatal, still claim lives. Biologic factors such as occult micrometastases at the time of diagnosis, aggressive histologic subtypes, and host immune factors all play a role. But the new work suggests that the social environment in which patients live is not merely background noise; it may be an independent and modifiable determinant of who survives. Kaltchenko and her colleagues, whose analysis was verified by co-authors and approved as exempt by the Johns Hopkins Institutional Review Board, have made their data available to other researchers upon reasonable request, an invitation for the field to build on the finding. As health systems grapple with persistent inequities in cancer outcomes, studies like this one sharpen the question from whether disadvantage matters to precisely where in the cancer care pathway it does its damage, and what can be done to interrupt it.

Subject of Research: The association between neighborhood socioeconomic deprivation and melanoma-specific mortality in patients with thin melanoma

Article Title: Area deprivation and melanoma-specific mortality in a high-risk referral cohort of patients with thin melanoma: a retrospective cohort study

Article References: Kaltchenko, M., Lalwani, K., Tripathi, R., Will, E., Herrera, D. B., Chen, N., Bibee, K., & Sunshine, J. (2026). Area deprivation and melanoma-specific mortality in a high-risk referral cohort of patients with thin melanoma: a retrospective cohort study. Archives of Dermatological Research, 318(1), Article 408. https://doi.org/10.1007/s00403-026-04911-1

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04911-1

Keywords: melanoma, thin melanoma, area deprivation, health disparities, melanoma-specific mortality, retrospective cohort study, dermatology, socioeconomic status, skin cancer, neighborhood disadvantage, survival outcomes, Johns Hopkins